• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
The Global Market For Sleep-Wake Disorders, 2005-2012: Trends, Opportunities, and Insights in A High-Value CNS Therapy Area Product Image

The Global Market For Sleep-Wake Disorders, 2005-2012: Trends, Opportunities, and Insights in A High-Value CNS Therapy Area

  • Published: December 2005
  • Region: Global
  • 78 Pages
  • Spectra Intelligence

FEATURED COMPANIES

  • ALLIANCE PHARMA
  • BOEHRINGER INGELHEIM
  • CYPRESS BIOSCIENCE
  • KYOWA PHARMACEUTICAL
  • NEUROGEN
  • PHERIN PHARMACEUTICALS
  • MORE

The market for sleep-wake disorders is expanding based on new indications and novel drugs which offer efficacious sleep solutions and wake-promoting effects while limiting adverse side effects that are associated with conventional drugs. In a global market estimated at US$4.3 billion and forecast to increase 158% to US$11 billion by 2012, drugs for sleep-wake disorders such as insomnia, excessive daytime sleepiness, shift-work sleep disorder, sleep apnoea, and restless legs syndrome are predicted to transform the market to a high-value CNS therapy area within a decade. Furthermore, new therapies in the pipeline that provide complete sleep solutions to patients with impaired sleep-wake rhythms or drugs that improve wakefulness in occupational settings will offer new market opportunities and treatment options.

Trailblazer Cephalon has been integral in expanding the wake-promotion sector with Provigil and has stimulated the market to develop more drugs for conditions such as sleep apnoea, occupational shift-work disorders, and delayed-phase circadian rhythm disorders. Despite an optimistic outlook, immediate challenges in the market include short-term saturation in the insomnia READ MORE >

CONTENTS
List of Tables
List of Figures
Executive Summary
Objectives of the Report
Research Methodology

Chapter 1 Introduction to Sleep-Wake Disorders
Sleep Disorders
Insomnia
Prevalence of Insomnia
Causes of Insomnia
Restless Legs Syndrome
Prevalence of Restless Legs Syndrome
Circadian Rhythm Sleep Disorders
Delayed Sleep Disorders
Shift-Work Sleep Disorder
Jet-Lag Sleep Disorders
Excessive Daytime Sleepiness and Narcolepsy
Narcolepsy
Prevalence of Narcolepsy
Neurobiological Basis to Narcolepsy
Treatments for Narcolepsy
Sleep Apnoea
Obstructive Sleep Apnoea
Prevalence of Obstructive Sleep Apnoea
Therapeutics for Sleep Apnoea

Chapter 2 The Market for Sleep-Wake Disorders
Sleep-Wake Disorders
Market Overview for Sleep-Wake Disorders
Insomnia
Wake-Promotion
Restless Legs Syndrome
Market Analysis for Sleep-Wake Disorder Drugs
- Insomnia
Market Analysis for the Insomnia Pharmacotherapies
Key Insomnia Drugs
Ambien/Stilnox/Stilnoct/Myslee (Zolpidem) - Sanofi-Aventis
Mechanism of Action
Efficacy
Reformulation
Sales Estimates
Commercial Outlook
Halcion (Triazolam) - Pfizer
Mechanism of Action
Reformulation
Sales Estimates
Commercial Outlook
Lunesta (Eszopiclone) - Sepracor
Mechanism of Action
Sales Estimates
Commercial Outlook
Rozerem (Ramelteon) - Takeda Pharmaceuticals
Mechanism of Action
Efficacy
Sales Estimates
Commercial Outlook
Sonata (Zaleplon) - Wyeth/King Pharmaceuticals
Mechanism of Action
Efficacy
Reformulation
Sales Estimates
Commercial Outlook
Premarket Focus - Late-Stage Development Drugs for Insomnia
Indiplon - Neurocrine Biosciences/Pfizer
Mechanisms of Action
Formulation Development
Efficacy
Commercial Prospects
Gaboxadol - Lundbeck/Merck & Co
Mechanisms of Action
Efficacy
Commercial Prospects
Other Pipeline Drug Candidates for Insomnia
Silenor (Doxepin) - Somaxon Pharmaceuticals
Posidorm - Alliance Pharma
Future Considerations and Market Outlook for the Insomnia Drug Market
- Wake-Promotion
Narcolepsy/Excessive Daytime Sleepiness
Market Analysis for Key Drugs for Narcolepy/Excessive Daytime Sleepiness
Provigil (Modafanil) - Cephalon
Mechanism of Action
Efficacy
Supplementary Indications
Reformulation
Sales Estimates
Commercial Prospects
Xyrem (Sodium oxybate) - Orphan Medical/Jazz Pharmaceuticals
Efficacy
Side Effects
Sales Estimates
Commerical Prospects
Future Considerations and Market Outlook for Wake-Promoting Drugs
- Restless Legs Syndrome
Requip/Adartrel/Repreve (Ropinirole) - GlaxoSmithKline
Mechanisms of Action
Efficacy
Sales Estimates
Commercial Outlook
Drugs in Development for Restless Legs Syndrome
Premarket Focus: Pramipexole - Boehringer Ingelheim
Efficacy
Commerical Prospects
- Sleep Apnoea - An Emerging High-Growth Sector
Obstructive Sleep Apnoea-Hyponoea Syndrome - An Underdiagnosed
Problem
Commercial Insights
Pipeline Focus
BTG/University of Illinois at Chicago
Organon/Cypress Bioscience
Future Considerations and Market Insights for Drugs to Treat Sleep
Disorders

Chapter 3 Drugs in Research and Development
Sleep-Wake Disorders
Research and Development Overview

Chapter 4 Market Analysis, Therapy Forecasting, and Prospect Mining
Sleep-Wake Disorders
Therapy Area Forecasts
Comparative Analysis: Sleep-Wake Disorder Product Sales
Prospect Mining
Sleep-Wake Disorder Prospects
Therapy Area Forecasts 2012 and 2020

Chapter 5 Report Synopsis
Sleep-Wake Disorders - Key Data Points
Bibliography and Reference Sources

List of Tables
Table 1.1 Insomnia Categorized by Duration of Symptoms
Table 1.2 Causes of Insomnia
Table 1.3 Symptoms of Narcolepsy
Table 1.4 Medical and Surgical Treatment Options for Sleep Apnoea
Table 2.1 Estimated Global Sales (US$) & Forecasts of Leading Drugs for Sleep-Wake
Disorders, 2004-20
Table 2.2 Marketed Drugs to Treat Insomnia, 2005
Table 2.3 Drugs in Development for Restless Legs Syndrome, 2005
Table 3.1 Drugs in Development for Sleep-Wake Disorders, 2005
Table 4.1 Global Market for Sleep-Wake Pharmacotherapies (US$m), 2004-2012
Table 4.2 Therapy Area Forecasts for Sleep-Wake Disorders, 2012 & 2020

List of Figures
Figure 2.1 Estimated Sales (US$) and Forecasts of Sleep-Wake Disorder Drugs
Segmented by Therapeutic Area, 2004-2012
Figure 2.2 Estimated Global Market Share of Sleep-Wake Disorder Drugs by
Therapy Area, 2005 & 2012
Figure 4.1 Sleep-Wake Disorder Therapy Area Forecasts, 2005 & 2012 (US$m)
Figure 4.2 Comparative Analysis of Leading Sleep-Wake Disorder Products,
2004-2012 (US$m)
Figure 4.3 Key Sleep-Wake Disorder Drug Prospects, 2005

The global market for sleep-wake disorders is worth an estimated US$4.3 billion in 2005 and is forecast to increase 158% to US$11 billion by 2012. Future high growth is anticipated based on the enlarging global markets for insomnia, excessive daytime sleepiness, shift-work sleep disorder, sleep apnoea, and restless legs syndrome. Furthermore, new therapies in the pipeline that provide complete sleep solutions to patients with impaired sleep-wake rhythms or drugs that improve wakefulness in occupational settings are expected to expand the market considerably in the medium term. Cephalon's trailblazing in wake-promotion with Provigil, for example, has created a major high growth market sector due to expanded indications into sleep apnoea and shift-work sleep disorder.

One of the immediate challenges in the insomnia market is short-term saturation - in the past year, three new products were approved, namely Ambien CR, Lunesta, and Rozerem, with up to four further drugs expected to be approved and launched over the next 18 months including Indiplon, Gaboxadol, Doxepin, and Posidorm. In view of expanded product choice companies will need to adopt aggressive marketing approaches and utilize key therapeutic differentiators to claim market share for their products. However, the majority of sleep-wake disorders are nderdiagnosed or misdiagnosed which indicates a significant market opportunity for manufacturers to redefine marketing strategies to optimize revenues for their products.

In this report, The Global Market for Sleep-Wake Disorders, 2005-2012: Trends, Opportunities, and Insights in a High-Value CNS Therapy Area, the reader will be introduced to an expanding specialty pharmaceutical market segment that is expected to more than double in value by 2012. The scope of the report comprises up-to-date coverage of epidemiological, aetiological, and therapeutic data related to sleep-wake disorders. Market insights and commercial opportunities are acquired through sector analysis of marketed and newly launched products, pipeline drugs, and company activities, in addition to comment on strategic and commercial issues that may affect product positioning and revenue optimization. The report also discusses key prospects that have the potential to become high revenue-earning products over the next decade.

Therapy area forecasting and illustrative comparative sales data is also presented to gain insight into leading products with sales estimates to 2012. Forecasting to 2020 is also detailed to enable the reader to make key assumptions about future markets and to enable the data to be utilized for proprietary predictive market modelling.

ALLIANCE PHARMA
ARENA PHARMACEUTICALS
BENTLEY PHARMACEUTICALS
BARR LABORATORIES
BIOVAIL
BOEHRINGER INGELHEIM
BTG
CARACO PHARMACEUTICALS
CEPHALON
CORTEX PHARMACEUTICALS
CYPRESS BIOSCIENCE
ELAN
FABRE-KRAMER PHARMACEUTICALS
GLAXOSMITHKLINE
JAZZ PHARMACEUTICALS
KING PHARMACEUTICALS
KYOWA PHARMACEUTICAL
LILLY
LUNDBECK
MERCK & CO
NEUROCRINE BIOSCIENCES
NEUROGEN
ORGANON
ORPHAN MEDICAL
PFIZER
PHASE 2 DISCOVERY
PHERIN PHARMACEUTICALS
QUESTCOR PHARMACEUTICALS
SANOFI-AVENTIS
SEPRACOR
SOMAXON PHARMACEUTICALS
SCHWARZ PHARMA
TAKEDA PHARMACEUTICALS
VANDA PHARMACEUTICALS
WYETH
XENOPORT

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos